# BridgeBio Pharma, Inc. Common Stock (BBIO) — Stock CV

BridgeBio Pharma, Inc. is a $12.8B healthcare company. Revenue grew 202.4% over the last year, it currently loses money, and it carries $1.26B of net debt.

> BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy.

## Identity

- **Ticker**: BBIO
- **Sector**: Healthcare
- **Industry**: Pharmaceutical Preparations
- **Headquarters**: PALO ALTO, CA
- **Employees**: 839
- **Website**: https://www.bridgebio.com
- **Market cap**: $12.8B
- **Last price**: $65.35
- **Financial profile**: Strained

## Vitals (TTM)

- **Revenue**: $713M
- **Net income**: -$692M
- **Free cash flow**: -$435M
- **Net debt**: $1.26B
- **Revenue growth (YoY)**: 202.4%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 25 |
| Growth | 25 |
| Profitability | 0 |
| Health | 15 |
| Quality | 30 |
| Moat | 25 |

## Qualifications (beginner checklist) — 3 of 9 passed

- [x] Revenue growing — +202.4% YoY
- [ ] Profitable — -$692M TTM
- [ ] Profit growing — -35.3% YoY
- [ ] Generates cash — -$435M TTM
- [x] Debt under control — current ratio 1.23
- [x] Established company — $12.8B market cap
- [ ] Not printing shares — +29.9% shares over ~5y
- [ ] Proven track record — 0/7 profitable years
- [ ] Financially stable — Altman Z -2.7 — distress

## Experience (career milestones)

- **FY2024** — Became debt-free: cash now exceeds total debt

## Strengths

- High gross margin (94.4%)
- Revenue growing 202.4% year over year

## Watch-outs

- Not profitable — 97.0% net margin
- Negative free cash flow (-$435.4M)
- Altman Z-Score -2.72 — elevated financial-distress risk
- Thin interest coverage (-2.2×)
- Loss-making in 7 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $69.7M | -$563M | -$511M |
| FY2022 | $77.6M | -$481M | -$424M |
| FY2023 | $9.30M | -$643M | -$529M |
| FY2024 | $222M | -$536M | -$522M |
| FY2025 | $502M | -$725M | -$447M |

---

Source: https://stockcv.com/BBIO — derived from company filings; may be delayed or incomplete. Information, not investment advice.